The Experts below are selected from a list of 153 Experts worldwide ranked by ideXlab platform

Steven C Schachter - One of the best experts on this subject based on the ideXlab platform.

  • Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
    Epilepsia, 2020
    Co-Authors: Jacqueline A French, Andres M Kanner, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Bassel Abou-khalil, Jocelyn Bautista, Thomas Browne, Steven C Schachter
    Abstract:

    To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. GBP can be effective for the treatment of Mixed Seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial Seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox-Gastaut syndrome. The choice of AED depends on Seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes for which more evidence is necessary.

  • Efficacy and Tolerability of the New Antiepileptic Drugs, II: Treatment of Refractory Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society
    Epilepsia, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Jocelyn F Bautista, Thomas R Browne, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Bassel Abou-khalil, Steven C Schachter
    Abstract:

    Summary: Purpose: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. Results: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. GBP can be effective for the treatment of Mixed Seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial Seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox–Gastaut syndrome. Conclusions: The choice of AED depends on Seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes for which more evidence is necessary.

  • efficacy and tolerability of the new antiepileptic drugs i treatment of new onset epilepsy report of the tta and qss subcommittees of the american academy of neurology and the american epilepsy society
    Epilepsia, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Jocelyn F Bautista, Bassel Aboukhalil, Thomas R Browne, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Steven C Schachter
    Abstract:

    Summary: Purpose: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. Results: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. GBP can be effective for the treatment of Mixed Seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial Seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox–Gastaut syndrome. Conclusions: The choice of AED depends on Seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes for which more evidence is necessary.

  • efficacy and tolerability of the new antiepileptic drugs i treatment of new onset epilepsy report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the american academy of neurology and the american epil
    Neurology, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Jocelyn F Bautista, Bassel Aboukhalil, Thomas R Browne, Cynthia L Harden, William H Theodore, Carl W Bazil, John M Stern, Steven C Schachter
    Abstract:

    Objective: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide—reviewed in the order in which these agents received approval by the US Food and Drug Administration) in the treatment of children and adults with newly diagnosed partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until September 2002, with selected manual searches up until 2003. Results: There is evidence either from comparative or dose-controlled trials that gabapentin, lamotrigine, topiramate, and oxcarbazepine have efficacy as monotherapy in newly diagnosed adolescents and adults with either partial or Mixed Seizure disorders. There is also evidence that lamotrigine is effective for newly diagnosed absence Seizures in children. Evidence for effectiveness of the new AEDs in newly diagnosed patients with other generalized epilepsy syndromes is lacking. Conclusions: The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those Seizure types and syndromes where more evidence is necessary.

  • Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American
    Neurology, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Bassel Abou-khalil, Jocelyn Bautista, Thomas Browne, Steven C Schachter
    Abstract:

    To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide) in the treatment of children and adults with refractory partial and generalized epilepsies. A 23-member committee including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until March 2003. All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. Gabapentin can be effective for the treatment of Mixed Seizure disorders, and gabapentin, lamotrigine, oxcarbazepine, and topiramate for the treatment of refractory partial Seizures in children. Limited evidence suggests that lamotrigine and topiramate are also effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox Gastaut syndrome. The choice of AED depends upon Seizure and/or syndrome type, patient age, concomitant medications, AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes where more evidence is necessary.

Steven J. Schiff - One of the best experts on this subject based on the ideXlab platform.

  • A Unified Framework for Neuronal Spikes, Seizures, Spreading Depression, and Ischemia-Induced Anoxic Depolarization
    Biophysical Journal, 2016
    Co-Authors: Ghanim Ullah, Steven J. Schiff
    Abstract:

    The pathological phenomena of Seizures and spreading depression have long been considered separate physiological events in the brain. By incorporating conservation of particles and charge, and accounting for the energy required to restore ionic gradients and cell swelling we extend the classic Hodgkin-Huxley formalism to uncover a unification of neuronal membrane dynamics. By examining the dynamics as a function of potassium and oxygen, we now account for a wide range of neuronal activities, from spikes to Seizures, spreading depression, Mixed Seizure and spreading depression states, and the terminal anoxic “wave of death.” Such a unified framework demonstrates that all of these dynamics lie along a continuum of the repertoire of the neuron membrane [1, 2]. We demonstrate the spontaneous transition between epileptic Seizure and spreading depression states as the cell swells and contracts in response to changes in osmotic pressure. The use of volume as an order parameter further revealed a dynamical definition for the experimentally described physiological ceiling that separates Seizure from spreading depression, as well as predicted a second ceiling that demarcates spreading depression from anoxic depolarization. Our model highlights the neuroprotective role of glial K+ buffering against Seizures and spreading depression, and provides novel insights into anoxic depolarization and the relevant cell swelling during ischemia [3]. Our results demonstrate that unified frameworks for neuronal dynamics are feasible, can be achieved using existing biological structures and universal physical conservation principles, and may be of substantial importance in enabling our understanding of brain activity and in the control of pathological states.[1] Wei, Ullah, and Schiff (2014) J.Neurosci. 34: 11733.[2] Wei, Ullah, Ingram, Schiff (2014) J. Neurophysiol. 112: 213.[3] Ullah et al (2015) PLoS Comp. Biol. 11: e1004413.

  • Unification in the control of spikes, Seizures, and spreading depression
    2015 American Control Conference (ACC), 2015
    Co-Authors: Steven J. Schiff
    Abstract:

    The pathological phenomena of spikes, Seizures and spreading depression have long been considered separate physiological events in the brain. By incorporating conservation of particles and charge, and accounting for the energy required to restore ionic gradients, we have recently extended the classic Hodgkin-Huxley formalism to uncover a unification of neuronal membrane dynamics (J Neuroscience 34:11733-11743, 2014). We now account for a wide range of neuronal activities, from spikes to Seizures, spreading depression, Mixed Seizure and spreading depression states, and the terminal anoxic “wave of death”. Such a unified framework demonstrates that all of these dynamics lie along a continuum of the repertoire of the neuron membrane. Our results demonstrate that unified frameworks for neuronal dynamics are feasible, can be achieved using existing biological structures and universal physical conservation principles, and can be utilized within a model based control framework in neural systems. Such a framework may be of substantial importance in enabling our further understanding of brain activity and in the control of pathological states.

  • ACC - Unification in the control of spikes, Seizures, and spreading depression
    2015 American Control Conference (ACC), 2015
    Co-Authors: Steven J. Schiff
    Abstract:

    The pathological phenomena of spikes, Seizures and spreading depression have long been considered separate physiological events in the brain. By incorporating conservation of particles and charge, and accounting for the energy required to restore ionic gradients, we have recently extended the classic Hodgkin-Huxley formalism to uncover a unification of neuronal membrane dynamics (J Neuroscience 34:11733–11743, 2014). We now account for a wide range of neuronal activities, from spikes to Seizures, spreading depression, Mixed Seizure and spreading depression states, and the terminal anoxic “wave of death”. Such a unified framework demonstrates that all of these dynamics lie along a continuum of the repertoire of the neuron membrane. Our results demonstrate that unified frameworks for neuronal dynamics are feasible, can be achieved using existing biological structures and universal physical conservation principles, and can be utilized within a model based control framework in neural systems. Such a framework may be of substantial importance in enabling our further understanding of brain activity and in the control of pathological states.

  • Unification of Neuronal Spikes, Seizures, and Spreading Depression
    The Journal of Neuroscience, 2014
    Co-Authors: Ghanim Ullah, Steven J. Schiff
    Abstract:

    The pathological phenomena of Seizures and spreading depression have long been considered separate physiological events in the brain. By incorporating conservation of particles and charge, and accounting for the energy required to restore ionic gradients, we extend the classic Hodgkin–Huxley formalism to uncover a unification of neuronal membrane dynamics. By examining the dynamics as a function of potassium and oxygen, we now account for a wide range of neuronal activities, from spikes to Seizures, spreading depression (whether high potassium or hypoxia induced), Mixed Seizure and spreading depression states, and the terminal anoxic “wave of death.” Such a unified framework demonstrates that all of these dynamics lie along a continuum of the repertoire of the neuron membrane. Our results demonstrate that unified frameworks for neuronal dynamics are feasible, can be achieved using existing biological structures and universal physical conservation principles, and may be of substantial importance in enabling our understanding of brain activity and in the control of pathological states.

Jacqueline A French - One of the best experts on this subject based on the ideXlab platform.

  • Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
    Epilepsia, 2020
    Co-Authors: Jacqueline A French, Andres M Kanner, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Bassel Abou-khalil, Jocelyn Bautista, Thomas Browne, Steven C Schachter
    Abstract:

    To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. GBP can be effective for the treatment of Mixed Seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial Seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox-Gastaut syndrome. The choice of AED depends on Seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes for which more evidence is necessary.

  • Efficacy and Tolerability of the New Antiepileptic Drugs, II: Treatment of Refractory Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society
    Epilepsia, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Jocelyn F Bautista, Thomas R Browne, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Bassel Abou-khalil, Steven C Schachter
    Abstract:

    Summary: Purpose: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. Results: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. GBP can be effective for the treatment of Mixed Seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial Seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox–Gastaut syndrome. Conclusions: The choice of AED depends on Seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes for which more evidence is necessary.

  • efficacy and tolerability of the new antiepileptic drugs i treatment of new onset epilepsy report of the tta and qss subcommittees of the american academy of neurology and the american epilepsy society
    Epilepsia, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Jocelyn F Bautista, Bassel Aboukhalil, Thomas R Browne, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Steven C Schachter
    Abstract:

    Summary: Purpose: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. Results: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. GBP can be effective for the treatment of Mixed Seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial Seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox–Gastaut syndrome. Conclusions: The choice of AED depends on Seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes for which more evidence is necessary.

  • efficacy and tolerability of the new antiepileptic drugs i treatment of new onset epilepsy report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the american academy of neurology and the american epil
    Neurology, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Jocelyn F Bautista, Bassel Aboukhalil, Thomas R Browne, Cynthia L Harden, William H Theodore, Carl W Bazil, John M Stern, Steven C Schachter
    Abstract:

    Objective: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide—reviewed in the order in which these agents received approval by the US Food and Drug Administration) in the treatment of children and adults with newly diagnosed partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until September 2002, with selected manual searches up until 2003. Results: There is evidence either from comparative or dose-controlled trials that gabapentin, lamotrigine, topiramate, and oxcarbazepine have efficacy as monotherapy in newly diagnosed adolescents and adults with either partial or Mixed Seizure disorders. There is also evidence that lamotrigine is effective for newly diagnosed absence Seizures in children. Evidence for effectiveness of the new AEDs in newly diagnosed patients with other generalized epilepsy syndromes is lacking. Conclusions: The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those Seizure types and syndromes where more evidence is necessary.

  • Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American
    Neurology, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Bassel Abou-khalil, Jocelyn Bautista, Thomas Browne, Steven C Schachter
    Abstract:

    To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide) in the treatment of children and adults with refractory partial and generalized epilepsies. A 23-member committee including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until March 2003. All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. Gabapentin can be effective for the treatment of Mixed Seizure disorders, and gabapentin, lamotrigine, oxcarbazepine, and topiramate for the treatment of refractory partial Seizures in children. Limited evidence suggests that lamotrigine and topiramate are also effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox Gastaut syndrome. The choice of AED depends upon Seizure and/or syndrome type, patient age, concomitant medications, AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes where more evidence is necessary.

William H Theodore - One of the best experts on this subject based on the ideXlab platform.

  • Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
    Epilepsia, 2020
    Co-Authors: Jacqueline A French, Andres M Kanner, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Bassel Abou-khalil, Jocelyn Bautista, Thomas Browne, Steven C Schachter
    Abstract:

    To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. GBP can be effective for the treatment of Mixed Seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial Seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox-Gastaut syndrome. The choice of AED depends on Seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes for which more evidence is necessary.

  • Efficacy and Tolerability of the New Antiepileptic Drugs, II: Treatment of Refractory Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society
    Epilepsia, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Jocelyn F Bautista, Thomas R Browne, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Bassel Abou-khalil, Steven C Schachter
    Abstract:

    Summary: Purpose: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. Results: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. GBP can be effective for the treatment of Mixed Seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial Seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox–Gastaut syndrome. Conclusions: The choice of AED depends on Seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes for which more evidence is necessary.

  • efficacy and tolerability of the new antiepileptic drugs i treatment of new onset epilepsy report of the tta and qss subcommittees of the american academy of neurology and the american epilepsy society
    Epilepsia, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Jocelyn F Bautista, Bassel Aboukhalil, Thomas R Browne, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Steven C Schachter
    Abstract:

    Summary: Purpose: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. Results: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. GBP can be effective for the treatment of Mixed Seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial Seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox–Gastaut syndrome. Conclusions: The choice of AED depends on Seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes for which more evidence is necessary.

  • efficacy and tolerability of the new antiepileptic drugs i treatment of new onset epilepsy report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the american academy of neurology and the american epil
    Neurology, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Jocelyn F Bautista, Bassel Aboukhalil, Thomas R Browne, Cynthia L Harden, William H Theodore, Carl W Bazil, John M Stern, Steven C Schachter
    Abstract:

    Objective: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide—reviewed in the order in which these agents received approval by the US Food and Drug Administration) in the treatment of children and adults with newly diagnosed partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until September 2002, with selected manual searches up until 2003. Results: There is evidence either from comparative or dose-controlled trials that gabapentin, lamotrigine, topiramate, and oxcarbazepine have efficacy as monotherapy in newly diagnosed adolescents and adults with either partial or Mixed Seizure disorders. There is also evidence that lamotrigine is effective for newly diagnosed absence Seizures in children. Evidence for effectiveness of the new AEDs in newly diagnosed patients with other generalized epilepsy syndromes is lacking. Conclusions: The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those Seizure types and syndromes where more evidence is necessary.

  • Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American
    Neurology, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Bassel Abou-khalil, Jocelyn Bautista, Thomas Browne, Steven C Schachter
    Abstract:

    To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide) in the treatment of children and adults with refractory partial and generalized epilepsies. A 23-member committee including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until March 2003. All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. Gabapentin can be effective for the treatment of Mixed Seizure disorders, and gabapentin, lamotrigine, oxcarbazepine, and topiramate for the treatment of refractory partial Seizures in children. Limited evidence suggests that lamotrigine and topiramate are also effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox Gastaut syndrome. The choice of AED depends upon Seizure and/or syndrome type, patient age, concomitant medications, AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes where more evidence is necessary.

Andres M Kanner - One of the best experts on this subject based on the ideXlab platform.

  • Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
    Epilepsia, 2020
    Co-Authors: Jacqueline A French, Andres M Kanner, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Bassel Abou-khalil, Jocelyn Bautista, Thomas Browne, Steven C Schachter
    Abstract:

    To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. GBP can be effective for the treatment of Mixed Seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial Seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox-Gastaut syndrome. The choice of AED depends on Seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes for which more evidence is necessary.

  • Efficacy and Tolerability of the New Antiepileptic Drugs, II: Treatment of Refractory Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society
    Epilepsia, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Jocelyn F Bautista, Thomas R Browne, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Bassel Abou-khalil, Steven C Schachter
    Abstract:

    Summary: Purpose: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. Results: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. GBP can be effective for the treatment of Mixed Seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial Seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox–Gastaut syndrome. Conclusions: The choice of AED depends on Seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes for which more evidence is necessary.

  • efficacy and tolerability of the new antiepileptic drugs i treatment of new onset epilepsy report of the tta and qss subcommittees of the american academy of neurology and the american epilepsy society
    Epilepsia, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Jocelyn F Bautista, Bassel Aboukhalil, Thomas R Browne, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Steven C Schachter
    Abstract:

    Summary: Purpose: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) [gabapentin (GBP), lamotrigine (LTG), topiramate (TPM), tiagabine (TGB), oxcarbazepine (OXC), levetiracetam (LEV), and zonisamide (ZNS)] in the treatment of children and adults with refractory partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane Library for relevant articles from 1987 to March 2003. Results: All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. GBP can be effective for the treatment of Mixed Seizure disorders, and GBP, LTG, OXC, and TPM for the treatment of refractory partial Seizures in children. Limited evidence suggests that LTG and TPM also are effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox–Gastaut syndrome. Conclusions: The choice of AED depends on Seizure and/or syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes for which more evidence is necessary.

  • efficacy and tolerability of the new antiepileptic drugs i treatment of new onset epilepsy report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the american academy of neurology and the american epil
    Neurology, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Jocelyn F Bautista, Bassel Aboukhalil, Thomas R Browne, Cynthia L Harden, William H Theodore, Carl W Bazil, John M Stern, Steven C Schachter
    Abstract:

    Objective: To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide—reviewed in the order in which these agents received approval by the US Food and Drug Administration) in the treatment of children and adults with newly diagnosed partial and generalized epilepsies. Methods: A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until September 2002, with selected manual searches up until 2003. Results: There is evidence either from comparative or dose-controlled trials that gabapentin, lamotrigine, topiramate, and oxcarbazepine have efficacy as monotherapy in newly diagnosed adolescents and adults with either partial or Mixed Seizure disorders. There is also evidence that lamotrigine is effective for newly diagnosed absence Seizures in children. Evidence for effectiveness of the new AEDs in newly diagnosed patients with other generalized epilepsy syndromes is lacking. Conclusions: The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those Seizure types and syndromes where more evidence is necessary.

  • Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American
    Neurology, 2004
    Co-Authors: Jacqueline A French, Andres M Kanner, Cynthia L Harden, William H Theodore, Carl W Bazil, John Stern, Bassel Abou-khalil, Jocelyn Bautista, Thomas Browne, Steven C Schachter
    Abstract:

    To assess the evidence demonstrating efficacy, tolerability, and safety of seven new antiepileptic drugs (AEDs) (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, and zonisamide) in the treatment of children and adults with refractory partial and generalized epilepsies. A 23-member committee including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until March 2003. All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial Seizures in adults. Gabapentin can be effective for the treatment of Mixed Seizure disorders, and gabapentin, lamotrigine, oxcarbazepine, and topiramate for the treatment of refractory partial Seizures in children. Limited evidence suggests that lamotrigine and topiramate are also effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox Gastaut syndrome. The choice of AED depends upon Seizure and/or syndrome type, patient age, concomitant medications, AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those Seizure types and syndromes where more evidence is necessary.